| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Linoleoyl phenylalanine targets inflammatory pathways, as N-acyl amines have been shown to have anti-inflammatory action. As a lipid signaling molecule, it may interact with G protein-coupled receptors (GPCRs) or other lipid-sensing receptors involved in inflammation and immune regulation. The compound is an endogenous N-acylamine, suggesting it plays a physiological role in lipid signaling. Its structure as a conjugate of linoleic acid and phenylalanine indicates potential for interactions with both lipid and amino acid sensing pathways.
|
|---|---|
| ln Vitro |
In vitro, Linoleoyl phenylalanine exhibits anti-inflammatory action. As an endogenous N-acyl amine found in Drosophila melanogaster larvae, it may play a role in insect physiology. The compound belongs to the N-acylamide family of lipid signaling molecules, which are known to modulate various physiological processes. However, detailed in vitro activity data including IC₅₀ values are not extensively published. Further studies are needed to characterize its biological activities.
|
| ln Vivo |
In vivo activity data for Linoleoyl phenylalanine are limited in the published literature. The compound is an endogenous N-acylamine and has been found in Drosophila melanogaster larvae, suggesting it has physiological roles in vivo. It has been shown to have anti-inflammatory action. However, detailed in vivo studies in mammalian models have not been extensively reported. Further research is needed to evaluate its in vivo efficacy and therapeutic potential.
|
| Enzyme Assay |
In vitro assays for Linoleoyl phenylalanine typically involve evaluation of anti-inflammatory activity. Immune cells are treated with the compound and stimulated with inflammatory stimuli, and cytokine production is measured by ELISA. The compound's structure can be confirmed by NMR and MS. Purity is typically assessed by HPLC with purity ≥97%. Receptor binding assays may be used to identify specific molecular targets.
|
| Cell Assay |
In vitro cellular assays for Linoleoyl phenylalanine typically involve evaluation of anti-inflammatory activity in immune cells such as macrophages or microglia. Cells are treated with the compound and stimulated with LPS or other inflammatory stimuli, and inflammatory mediator production (TNF-α, IL-1β, IL-6, NO) is measured. Cytotoxicity is assessed using standard cell viability assays. The compound is stored as powder at -20°C for 3 years or 4°C for 2 years.
|
| Animal Protocol |
In vivo animal experiments for Linoleoyl phenylalanine have not been extensively reported. Based on its anti-inflammatory activity, potential studies could include rodent models of acute or chronic inflammation with oral or intraperitoneal administration of the compound. Endpoints would include inflammatory cytokine levels, tissue histopathology, and clinical signs. However, such studies have not been published for this specific compound to date.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Linoleoyl phenylalanine are characteristic of long-chain N-acyl amino acids. The compound has a molecular weight of 427.62 g/mol and molecular formula C₂₇H₄₁NO₃. As a lipophilic lipid signaling molecule, it is expected to have good membrane permeability and tissue distribution. The compound may be transported in plasma bound to proteins and metabolized by fatty acid amide hydrolase (FAAH) or other enzymes. Storage: powder at -20°C for 3 years or 4°C for 2 years.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Linoleoyl phenylalanine is not extensively documented. As an endogenous N-acylamine found in Drosophila larvae, it is expected to have a relatively favorable safety profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Linoleoyl phenylalanine (CAS# 2441-64-7, molecular formula C₂₇H₄₁NO₃, molecular weight 427.62) is an endogenous N-acyl amine and lipid signaling molecule. It is a conjugate of linoleic acid and phenylalanine with anti-inflammatory action. Also known as N-linoleoyl phenylalanine. No clinical trials or regulatory approvals have been identified. Storage: powder at -20°C for 3 years or 4°C for 2 years.
|
| Molecular Formula |
C27H41NO3
|
|---|---|
| Molecular Weight |
427.619348287582
|
| Exact Mass |
427.308
|
| CAS # |
2441-64-7
|
| PubChem CID |
89824941
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.008±0.06 g/cm3(Predicted)
|
| Boiling Point |
614.9±55.0 °C(Predicted)
|
| LogP |
7.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
31
|
| Complexity |
521
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(O)(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCCCCCC/C=C\C/C=C\CCCCC
|
| InChi Key |
HKUGGWURERXWKM-ABDCMALPSA-N
|
| InChi Code |
InChI=1S/C27H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-26(29)28-25(27(30)31)23-24-20-17-16-18-21-24/h6-7,9-10,16-18,20-21,25H,2-5,8,11-15,19,22-23H2,1H3,(H,28,29)(H,30,31)/b7-6-,10-9-/t25-/m0/s1
|
| Chemical Name |
(2S)-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]-3-phenylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3385 mL | 11.6926 mL | 23.3852 mL | |
| 5 mM | 0.4677 mL | 2.3385 mL | 4.6770 mL | |
| 10 mM | 0.2339 mL | 1.1693 mL | 2.3385 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
